Drug Discovery World

AUGUST 14, 2023

Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. In cancer, PGE2 acts in the tumour microenvironment to trigger cancer cells to evade the immune system.

Trials 130

Trials Small Molecule Pharmacokinetics Clinical Trials 130

Drug Discovery World

OCTOBER 4, 2022

New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

Drug Discovery World

AUGUST 17, 2022

The funding, which is being provided under the EIB’s venture debt instrument, will help Ryvu finance its development pipeline of new cancer treatments from discovery through to clinical trials. Ryvu is one of the main employers of biotech researchers in Poland. EIB Vice-President?Teresa Teresa Czerwin?ska?said:

Small Molecule 130

Small Molecule Clinical Trials Clinical Development Treatment 130

Drug Discovery World

OCTOBER 14, 2022

million in potential future payments based on agreed preclinical, clinical development, and commercial milestones. Despite decades of effort, many targets remain inaccessible to traditional small molecule drugs, and many others have uncertain relevance to disease,” commented Vividion Therapeutics CEO Jeffrey Hatfield.

Small Molecule 130

Small Molecule Clinical Development Therapies Treatment 130

The Pharma Data

NOVEMBER 19, 2020

The Company is also aiming to leverage the highly conserved structure of the SARS-CoV-2 M pro protease as a basis for the design of novel oral small molecules against predicted future variants of SARS-CoV-2 and other related human viruses. References. Hilgenfeld, Febs J. 2014), 281, 4085-4096. Pillaiyar, et al, J.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

Drug Discovery World

FEBRUARY 16, 2023

Amy Berrington and Montserrat Garcia-Closas, Institute of Cancer Research: Professors Amy Berrington and Montserrat Garcia-Closas have been appointed as Team Leaders at the Institute of Cancer Research’s Division of Genetics and Epidemiology. So who are the latest movers and shakers? Wang Zilong, H.E.L Group: H.E.L

Small Molecule 130

Small Molecule Pharmaceuticals Clinical Development Science 130

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. The lead candidate, HTL0022562, has advanced through preclinical development demonstrating promising and differentiated properties for further investigation in human trials. Vlad Coric , M.D.,

Small Molecule 40

Small Molecule Licensing Licensing Clinical Trials 40

Drug Discovery World

JANUARY 15, 2024

Evotec and the Crohn’s & Colitis Foundation Evotec has joined forces with the Crohn’s & Colitis Foundation, a non-profit organisation focused on research and patient support for inflammatory bowel disease (IBD). Under the amended agreement, VantAI will be eligible to receive up to $1.25

Targeted Protein Degradation 147

Targeted Protein Degradation Drugs Small Molecule Licensing 147

Drug Target Review

OCTOBER 11, 2023

Autophagy in a hot topic in scientific circles; the number of papers that mention the process has risen almost exponentially since Yoshinori Ohsumi was awarded the Nobel Prize in 2016 for his research into its underlying mechanisms. Autophagy boosters, in contrast, are conventional small molecule drugs. cited 2023 Sep 5].

Disease 113

Disease Treatment Small Molecule Therapies 113

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1.

Marketing 245

Marketing FDA Approval Licensing Licensing 245

Drug Discovery World

JANUARY 4, 2024

ANX1502 is a first-in-kind oral, selective small molecule inhibitor that targets the active form of C1s responsible for propagating classical pathway activation in association with C1q. No serious adverse events were reported, and there were no significant clinical or lab findings.

Small Molecule 130

Small Molecule Pharmacokinetics Clinical Development Disease 130

LifeSciVC

JANUARY 16, 2024

The market for each target class likely asymptotes with the number of Pharma or large biotech who can clinically develop and commercialize such assets; thus, there is intense focus on the first handful of assets to market. Small molecule GLP1s?

Small Molecule 140

Small Molecule Trials Therapies Disease 140

The Pharma Data

NOVEMBER 18, 2021

— Gilead Exercises Options to Arcus’s Anti-TIGIT Program (Domvanalimab and AB308), Etrumadenant (A2a/A2b Adenosine Receptor Antagonist) and Quemliclustat (Small Molecule CD73 Inhibitor) — — Arcus to Receive Option Payments Totaling $725 million — Gilead Lores,Inc. Nasdaq GILD) and Arcus Biosciences,Inc.

Research 52

Research Small Molecule Clinical Development Packaging 52

Drug Target Review

JULY 18, 2024

Beyond the standard tumour-informed assay, we collaborated with Natera to create a more sensitive tumour-informed test using its Signatera molecular residual disease testing technology for research use in our AMPLIFY-201 clinical trial. This helped us to identify as many patients as possible who already had microscopic tumour spread.

Drug Development 59

Drug Development Clinical Trials Drugs Small Molecule 59

The Pharma Data

APRIL 11, 2023

Bayer is progressing novel research around its prostate cancer treatment darolutamide. Both small molecule inhibitors in Immuno-Oncology are being jointly developed in a strategic research alliance with the German Cancer Research Center (DKFZ) in Heidelberg, Germany.

Research 40

Research Clinical Trials Small Molecule Pharmacokinetics 40

Drug Target Review

MAY 1, 2024

The advent of monoclonal antibodies paired with improvements in each ADC design component has led to the approval of 11 ADCs with more than 180 ADCs currently in clinical development. He has more than 25 years of US-based experience in biologics drug discovery and development in biotechnology research.

Drugs 69

Drugs FDA Approval Organic Chemistry Small Molecule 69

LifeSciVC

APRIL 2, 2024

We are turning a corner, and optimistically that means more private companies will be able to secure the resources they need to advance groundbreaking research through critical value inflection points. We experienced strong enthusiasm for small molecule research in the investor community. What resonated?

Science 68

Science Small Molecule International Clinical Development 68

The Pharma Data

MAY 15, 2023

The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. Executive Vice President, Research, Gilead Sciences. The company was founded in 2021 by Stephen Kaldor, Ph.D., Qing Dong, Ph.D., and Gene Hung, M.D.,

Small Molecule 40

Small Molecule DNA Immune Response Science 40

Drug Discovery World

JUNE 5, 2023

Meet the biotech: Enhanc3D Genomics Enhanc3D Genomics was spun out from the laboratories of Dr Stefan Schoenfelder and Professor Peter Fraser, who pioneered research into the dynamic spatial organisation of the genome at the Babraham Institute in Cambridge, UK.

Small Molecule 130

Small Molecule Treatment Science Disease 130

The Pharma Data

MARCH 28, 2022

Our Research & Development (R&D) teams are following the science to control chronic inflammation and collaborating with leading experts across all sectors to address both urgent and growing patient needs. Two complementary candidates for COPD , developed in collaboration with Regeneron, targeting distinct subpopulations.

Small Molecule 52

Small Molecule Clinical Development Disease Science 52

Sygnature Discovery

NOVEMBER 29, 2023

QN-302 has been conceived to work by selectively stabilizing G-quadruplex complexes prevalent in the promoter region of cancer-related genes in many tumor types, impeding the function of these cancer genes, and may therefore potentially offer a tumor-selective clinical approach to treatment. Qualigen Therapeutics’ Chief Medical Officer.

Clinical Trials 52

Clinical Trials Treatment Trials Small Molecule 52

Drug Target Review

JULY 18, 2023

AI is being used to find the targets themselves, design the drugs to manipulate that biology, and thirdly, AI is being used to support validation of those targets and drugs as part of pre-clinical development. There is a plethora of data available to researchers, but it is not all standardised and lacks the same metadata.

Drug Development 98

Drug Development Drugs Pharmaceutical Companies Clinical Development 98

Drug Discovery World

FEBRUARY 5, 2024

Here, experts weigh in on what to expect from cancer research and immunotherapies. Dr Gen Li, Founder and President, Phesi “In 2024, we can expect immunotherapy trials to become a driving force for change in clinical development. This is part of a series of predictions based on different themes.

Research 290

Research Small Molecule Clinical Trials Immune Response 290

Drug Discovery World

OCTOBER 16, 2023

Here, DDW’s Megan Thomas highlights the research taking place and where this is happening. This environment of research excellence, in turn, fosters R&D, innovation, spin-offs, start-ups, networking, collaboration and entrepreneurship, which sets a sturdy foundation that attracts funding, and creates an appealing work culture.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

The Pharma Data

SEPTEMBER 25, 2020

ICR and Cancer Research UK spinout closes Series B financing. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. Source link.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Clinical Development Disease 40

The Pharma Data

MAY 31, 2022

We look forward to continuing our collaboration with Biogen and the Parkinson’s community in our unified goal to develop BIIB122 as a potential treatment option for people and families living with Parkinson’s disease.”. BIIB122 is an investigational small molecule inhibitor of LRRK2 that was discovered and developed by Denali.

Disease 52

Disease Small Molecule Biosimilars Engineering 52

The Pharma Data

JANUARY 13, 2021

Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need. Knopp’s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma.

Trials 52

Trials Small Molecule Clinical Trials Treatment 52

Sygnature Discovery

NOVEMBER 29, 2023

QN-302 has been conceived to work by selectively stabilizing G-quadruplex complexes prevalent in the promoter region of cancer-related genes in many tumor types, impeding the function of these cancer genes, and may therefore potentially offer a tumor-selective clinical approach to treatment. Qualigen Therapeutics’ Chief Medical Officer.

Clinical Trials 40

Clinical Trials Treatment Trials Small Molecule 40

The Pharma Data

JUNE 28, 2021

Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer. Xofigo is currently under further evaluation in a broad clinical development program in prostate cancer and beyond.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

LifeSciVC

MARCH 1, 2023

Importantly, they also pointed to something that we at HotSpot Therapeutics and a small group of other researchers and companies recognized several years ago – that scientific advances have made this attractive, but once considered ‘undruggable,’ target druggable.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

The Pharma Data

OCTOBER 18, 2020

Dr. Berk, commented “I am excited to join the Board of Inflection Biosciences as it advances its novel PIM/PI3K inhibitor, IBL-202, towards clinical development for unmet needs in B-cell malignancies and other cancers.”. Dr. Berk most recently has served as a consultant to several companies developing oncology therapies.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

DECEMBER 10, 2020

executive vice president of research and development. “We We look forward to working closely with the FDA throughout the clinical development process to bring this potential new innovative treatment to patients as quickly as possible.”. About LX9211. Safe Harbor Statement.

FDA 52

FDA Pharmaceuticals Small Molecule Clinical Development 52

Precision for Medicine

JUNE 26, 2023

Our partnerships are with the most innovative organizations, utilizing the most advanced, cutting-edge technologies and providing us with unparalleled experience in manufacturing small molecule, biologics and next-generation medicines,” said John Khoury, Executive Vice President at Project Farma. Bethesda, Md.,

Science 40

Science Small Molecule Clinical Research Engineering 40

The Pharma Data

DECEMBER 21, 2020

Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. The principle of TPD is to use small molecules to commit the target protein into the E3 ligase-mediated degradation pathway thereby eliminating or reducing its activity.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

The Pharma Data

OCTOBER 27, 2020

Mirati Therapeutics is a San Diego -based late-stage biotechnology company relentlessly focused on translating drug discovery and research into new treatments for patients by advancing and delivering novel therapeutics that target the genetic and immunologic drivers of cancer. About Mirati Therapeutics.

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

The Pharma Data

FEBRUARY 21, 2022

Bayer’s research and development pipeline continues to grow as the company is building on its existing competencies, such as the expertise around small molecules, while expanding into new modalities, including cell and gene therapies.

Small Molecule 52

Small Molecule Clinical Trials Clinical Development Production 52

The Pharma Data

DECEMBER 17, 2020

Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group. He spent 27 years at Merck & Co.

Small Molecule 52

Small Molecule Engineering Pharmaceuticals Clinical Development 52